-
effectivehealthcare.ahrq.gov/sites/default/files/cer-242-radiation-therapy-brain-metastases-disposition-comments.pdf
June 09, 2021 - In addition, the key
questions listed demonstrate the main points
discussed in the entire report. … Reviewer #1
Results Page 56-57 of 280
Serious adverse events- Please include citations
for the studies discussed … 57 of 280
No. of adverse events and Radiation necrosis-
Please include citations for the studies discussed … Peer
Reviewer #1
Results Page 57-58 of 280
Headaches- Please include citations for the
studies discussed … #1
Results Page 59 of 280
Fatigue, Seizure, Vomiting- Please include
citations for the studies discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-pain-opioid-treatment_disposition-comments.pdf
September 29, 2014 - Comparisons with prior reviews are concisely and clearly discussed. … The
mentioned reviews and others are
Discussed for contextual purposes. … I would also recommend consistency
in the report in the order in which these are discussed. … This association is not intuitive and is not commonly discussed. … The
results of the American Pain Society
review are discussed throughout the
report.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-214-afib-disposition-comments.pdf
October 30, 2019 - don’t think
you necessarily need to change the inclusion
criteria at this point, but this should be discussed … As discussed
there is sparse data evaluating
direct comparisons.
118. … The study by Hijazi was
included in our report and is
discussed in the subgroup table
within KQ3. … rivaroxaban for nonvalvular AF;”
however BI notes that data from Gorst-Rasmussen
et al. (2016) is not discussed … Peer Reviewer #5 Clarity/
Usability
See general comments (#s 24-36) No response needed –
discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/gout-management-disposition-160721.pdf
March 15, 2016 - ES-2, line 15: Regarding the management that is discussed about gout (as opposed
to “chronic gout”). … The IL-1 antagonists
should be discussed as the treatments for gout; they are not used to lower urate … TEP Reviewer #3 Results Full Report:• Page 34 of 176: IL-1B antagonists should not be discussed under … management of hyperuricemia; they should be discussed under management of gout
attacks. … I believe that this is what rheumatologists and the
FDA have been doing as discussed above.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-mobile-devices_research-protocol.pdf
July 12, 2017 - As discussed in the previous section, we will use a hierarchical approach to reviewing the
evidence, … These challenges will be discussed with key informants and other
topic experts to identify which challenges
-
effectivehealthcare.ahrq.gov/sites/default/files/politi.pdf
May 29, 2025 - Politi
Slide
1: Supporting
Shared Decisions When Clinical Evidence
is Low
Mary C. Politi, Ph.D.
Department of Surgery, Division of
Public Health Sciences
Washington University in St. Louis School of Medicine
Slide
2: Overview
• Brief overview of Shared Decis…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/stroke-atrial-fibrillation_disposition-comments.pdf
August 23, 2013 - We have discussed this potential limitation in the
Discussion section. … It seems like in the conclusions harms of newer
antithrombotics were not really discussed, in
particular … Thank you for this comment; we agree that the INR control discussed in
this statement refers to center-based … TEP #3 Methods Generally OK
Page 18, last para - limitations of c-statistics should
be discussed, … This should be discussed
We have noted that CHA2DS2-VASc is used more commonly in Europe
and has been
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-237-integrating-palliative-care-disposition-comments.pdf
February 11, 2021 - interdisciplinary approach to care,
which did not appear to come
through in most of the studies
discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/registries-forums_research_0.pdf
May 01, 2014 - Web-based collaborative forum” reflects the broader concept of a “community of
practice” (CoP), as discussed … Having found that a need for a
CoP existed, stakeholders then discussed the value that they would draw … These issues are
summarized below, and are discussed in more detail in the Recommendations section of … Finally, a Web site can offer
concrete tools, which are discussed further in the subsequent sections … If the
funding structure or governance of the Web-based CoP discussed in this report includes AHRQ,
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/weight-loss-surgery_disposition-comments.pdf
June 05, 2013 - Summary
Need to discuss adverse events by surgical procedure as they
differ
Adverse events are discussed … Peer Reviewer 5 Methods It looks like individual drug and lifestyle studies were only
discussed in … Blood
pressure, cholesterol, and QOL from the O’Brien study
are discussed in the accompanying text. … The appropriate literature is concluded, and discussed. … This issue is discussed in the applicability section.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/deliberative-methods_presentation-2013.pdf
January 01, 2013 - Community Forum: Introduction to Online Tools To Support Public Deliberation
This presentation introduces online tools that can be used to support public deliberation.
During this presentation, we discuss the types of online tools that can be used to support
public deliberation and what to consider when select…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-256-telehealth-women-disposition-comments.pdf
June 16, 2022 - Disposition of Comments_Comparative Effectiveness Review No. 256: Effectiveness of Telehealth for Women's Preventive Services
Comparative Effectiveness Review Disposition of Comments Report
Title: Effectiveness of Telehealth for Women’s Preventive Services
Draft report available for public comment…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/fibromyalgia_disposition-comments.pdf
January 26, 2015 - Outcomes for men (vs. women) are
discussed on page 18 of the report under
Results by Sex. … Looking only
at the psychological treatments, only 4 studies could be
discussed. … questions are truely important, a case for
answering the questions should be made and the lack of
data discussed … conclusions about the equivicality of need for more
intensive care for subgroups cannot be reliably discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-257-antenatal-care-disposition-comments.pdf
June 28, 2022 - changes to the schedule of visits and televisits for routine
antenatal care need to be more prominently discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-217-management-of-infertility-comments.pdf
May 14, 2019 - This was discussed with the TEP
and is admittedly a trade-off. … This point was discussed with the
TEP, who agreed that limiting to
live birth was appropriate; we have … Jessica Goldstein
(Public Reviewer
#1)
Results Elective single-embryo transfer (eSET) discussed in
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/scarce-resources-protocol.pdf
January 01, 2013 - of
the findings was assessed, and (5) potential confounders to the strategy’s effectiveness were
discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-260-improved-cancer-outcomes-disposition-comments.pdf
May 22, 2023 - Disposition of Comments_Comparative Effectiveness Review No. 260: Nutrition as Prevention for Improved Cancer Health Outcomes
Comparative Effectiveness Review Disposition of Comments Report
Title: Nutrition as Prevention for Improved Cancer Health Outcomes
Draft report available for public comment…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-treatment_disposition-comments.pdf
September 10, 2012 - reported under KQ1b and also included in the
discussion, where addition certification issues are
discussed … Added text to Methods to clarify that these results are
discussed under kq1b and 2b. … Reviewer 2 Summary and
Discussion
The limitations discussed were right on target.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/acs-pci-adjunctive-devices_disposition-comments.pdf
March 01, 2012 - give the reader an
overview of the trials which were summarize
quantitatively separately from those discussed … might object to the
use of random effects model – see AHRQs guidance for rare
events
This topic was discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-disposition-comments.pdf
August 29, 2023 - The EPC sought clarification on
the requests and discussed them
with ASTRO.